Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

Iain C. MacDougall*, Simon D. Roger, Angel De Francisco, David J.A. Goldsmith, Huub Schellekens, Hans Ebbers, Wolfgang Jelkmann, Gérard London, Nicole Casadevall, Walter H. Hörl, David M. Kemeny, Carol Pollock

*Corresponding author for this work
83 Citations (Scopus)

Abstract

Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

Original languageEnglish
JournalKidney International
Volume81
Issue number8
Pages (from-to)727-732
Number of pages6
ISSN0085-2538
DOIs
Publication statusPublished - 02.04.2012

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Dive into the research topics of 'Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights'. Together they form a unique fingerprint.

Cite this